This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Santen Pharmaceutical Co., Ltd.

Drug Names(s): ONO-9054

Description: ONO-9054 is an eye drop formulation of an agonist of the prostaglandin (PG) FP and EP3 receptors.

Deal Structure: ONO and Santen
In March 2016, Santen Pharmaceutical and ONO Pharmaceutical announced that they have entered an exclusive licensing agreement whereby Santen will develop and commercialize ONO-9054 on a worldwide basis.

Under the terms of the agreement, ONO will receive from Santen an upfront payment. In addition, ONO will also receive future milestone payments based upon achievement of certain development and its sales, as well as the sales-based royalties after the launch of the product.

Partners: Ono Pharmaceutical Company, Ltd.

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug